Wenyuan Shi, PhD

Wenyuan Shi,
PhD

CEO/Chief Scientific Officer, Forsyth Institute; Professor/Chair of UCLA Dental School Oral Biology Department

Precision Medicine Approach To Oral Health

with Wenyuan Shi, PhD

Chief Executive Officer, ADA Forsyth Institute

 

The history of dentistry is full of disruptive events impacted by innovative products or technologies.  From refined sugar to fluoride, to implant, to clear aligners, each made a unique impact on oral health.  With the dental market growing exponentially, and people living much longer, and hundreds of new dental technology companies appearing, along with investors focused on oral health technology innovation increasing, what is the next big thing in dentistry?  Although we do not have a crystal ball, there are a few key areas to watch.  Dentistry will likely follow medicine and transition from a surgical model to a preventative model of care. Many new diagnostic and therapeutic tools for managing dental diseases are being developed. This presentation will provide an overview on these exciting new developments.

This course will award 1.5 units of category 1 continuing education credit.

 

 

Biography

Dr. Wenyuan Shi is currently the Chief Executive Officer of The ADA Forsyth Institute, a world class dental research institute.  Prior to this position, Dr. Shi was the chairman and professor of Oral Biology at UCLA School of Dentistry as well as the Professor of Microbiology, Immunology and Molecular Genetics at UCLA School of Medicine for 23 years, then joined The Forsyth Institute as the president and CEO in 2017.  Scientifically, Dr. Shi has been leading 20+ NIH grants to use multidisciplinary approaches to study oral microbial pathogenesis with a specific focus on oral microbiome, bacterial inter-species interaction and signal transduction.  Technologically, Dr. Shi is actively involved in the development of next generation of diagnostic and therapeutic tools against oral microbial infections, including saliva diagnosis of oral pathogens and peptide based targeted antimicrobial therapeutics.  These translational research efforts have resulted in novel technologies that were licensed and developed by major pharmaceutical, dental and biotech companies. 

 

Dr. Shi was the founding scientist, former chief scientific officer and chairman of the scientific advisory board of C3J Therapeutics Inc., which is now called Armata Pharmaceuticals (https://www.armatapharma.com), listed on NYSE.  Administratively, Dr. Shi has been leading a three-pillared strategic plan at the Forsyth Institute (now the ADA Forsyth Institute) for its cutting-edge dental research, technology development and global expansion since 2017.

 

Dr. Shi obtained his BS degree (biology) from Fudan University (Shanghai) in 1984, acquired his Ph.D degree (Genetics) from University of Wisconsin-Madison in 1991 and fulfilled his postdoctoral training at University of California-Berkeley during 1992-1995.  He is co-author and co-inventor of over 280 scientific articles and 40+ patents and patent applications.  Research.com indicates that Dr. Shi has a D-index 74 and citation 17836, ranking among top 10 best oral microbiologists in USA.